Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma
- PMID: 9579845
- PMCID: PMC2150168
- DOI: 10.1038/bjc.1998.225
Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma
Abstract
Adjuvant chemotherapy with fluorouracil (FU) and levamisole or FU/leucovorin (LV) has been established as effective adjuvant treatment for patients with stage III colon cancer. Among several other promising treatment strategies in resected colon cancer, intraperitoneal anti-cancer drug administration with its appealing rationale of counteracting microscopic residual disease on peritoneal surfaces and occult metachronous liver metastases by achieving high intraportal drug concentrations has not yet undergone sufficient clinical evaluation. To determine whether a combination of this locoregional therapeutic concept with systemic intravenous administration of FU/LV would yield better results than conventional adjuvant chemoimmunotherapy with FU/levamisole, the present randomized study was initiated. A total of 241 patients with resected stage III or high-risk stage II (T4N0M0) colon cancer were randomly assigned to 'standard therapy' with FU and levamisole, given for a duration of 6 months, or to an investigational arm, consisting of LV 200 mg m(-2) plus FU 350 mg m(-2), both administered intravenously (days 1-4) and intraperitoneally (days 1 and 3) every 4 weeks for a total of six courses. In patients with stage II disease, no significant difference was noted between the two arms after a median follow-up time of 4 years (range 2.5-6 years). Among 196 eligible patients with stage III disease, however, a comparative analysis of the two treatment groups suggested both an improvement in disease-free survival (P = 0.0014) and a survival advantage (P = 0.0005), with an estimated 43% reduction in mortality rate (95% confidence interval 26-70%) in favour of the investigational arm. In agreement with its theoretical rationale, combined intraperitoneal and intravenous FU/LV was particularly effective in reducing locoregional tumour recurrences with or without liver or other organ site involvement (9 vs 25 patients in the FU/levamisole arm; P = 0.005). Treatment-associated side-effects were infrequent and generally mild in both arms, although a lower rate of severe (WHO grade 3) adverse reactions was noted in patients receiving locoregional plus intravenous chemotherapy (3% vs 12%; P = 0.01). The results of this trial suggest that combined intraperitoneal plus systemic intravenous chemotherapy with FU/LV is a promising adjuvant treatment strategy in patients with surgically resected stage III colon carcinoma.
Similar articles
-
Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.J Clin Oncol. 2001 Mar 15;19(6):1787-94. doi: 10.1200/JCO.2001.19.6.1787. J Clin Oncol. 2001. PMID: 11251010 Clinical Trial.
-
Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma.Eur J Cancer. 1995 Nov;31A(12):1981-6. doi: 10.1016/0959-8049(95)00426-2. Eur J Cancer. 1995. PMID: 8562152 Clinical Trial.
-
5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.Ann Oncol. 2003 Mar;14(3):395-9. doi: 10.1093/annonc/mdg100. Ann Oncol. 2003. PMID: 12598344 Clinical Trial.
-
An overview of adjuvant systemic chemotherapy for colon cancer.Clin Colorectal Cancer. 2004 Jun;4 Suppl 1:S22-8. Clin Colorectal Cancer. 2004. PMID: 15212702 Review.
-
A systematic overview of chemotherapy effects in colorectal cancer.Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367. Acta Oncol. 2001. PMID: 11441937 Review.
Cited by
-
Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial.Ann Surg. 2000 Apr;231(4):449-56. doi: 10.1097/00000658-200004000-00001. Ann Surg. 2000. PMID: 10749603 Free PMC article. Clinical Trial.
-
Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer.Oncol Lett. 2012 Dec;4(6):1309-1314. doi: 10.3892/ol.2012.914. Epub 2012 Sep 13. Oncol Lett. 2012. PMID: 23205128 Free PMC article.
-
Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.Clin Pharmacokinet. 2012 Apr 1;51(4):203-24. doi: 10.2165/11598890-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22420577 Review.
-
Intraperitoneal chemotherapy: biologic implications for clinical outcome.Ann Surg. 2000 Apr;231(4):457-9. doi: 10.1097/00000658-200004000-00002. Ann Surg. 2000. PMID: 10749604 Free PMC article. No abstract available.
-
Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review.Br J Cancer. 2014 Sep 9;111(6):1112-21. doi: 10.1038/bjc.2014.369. Epub 2014 Jul 15. Br J Cancer. 2014. PMID: 25025964 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources